Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Rivia launches AI-powered clinical trial data review module, with Scancell as early adopter
(1h)
Valo and Montai become one as the Flagship AI-based biotechs tie the knot
(4h)
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
(5h)
BioPharma Dive
Drug price hikes in Germany could push US costs higher, study says
(3h)
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
(5h)
PepGen soars on promising early data for muscular dystrophy drug
(21h)
Endpoints News
Flagship merges two startups; J&J scores a bipolar mania success
(3h)
Beeline reveals Phase 2 lupus data from old Bristol Myers drug
(5h)
UK science minister calls for more life sciences investment
(5h)
BioSpace
FDA warns Chinese providers of compounding APIs over record-request refusals
(3h)
PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
(4h)
Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
(4h)
STAT News
What MAHA’s support for Russell Brand tells us about the movement
(1h)
BMI alternative would flip obesity diagnosis for millions, study finds
(3h)
Why this former ER doc thinks giving AI less information is sometimes better
(4h)
BioPharma Trend
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Tzuchman-Katz
(1d)
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Zucman-Katz
(2d)
The $1.8 Billion Bet That More Data Will Enable Progress in Virtual Cells
(1w)
Drug Channels
The State of Employer Pharmacy Benefits in 2026: When Plan Savings Come From Higher Patient Costs
(1d)
BlinkRx Insights: Clarifying the Mystery around “DTP”
(5d)
Disintegration: Adam’s Four Takeaways from the CVS Health Breakup
(6d)
European Biotechnology Magazine
VectorY secures €74.5M to advance ALS gene therapy trial
(5h)
Austria builds life sciences momentum
(5h)
SRTD raises €31.5M seed round to develop cell-selective RNA therapies
(1d)
Drug Hunter
DNA-Encoded Libraries Expand the Reach of Hit Discovery
(4h)
GSK3882347
(1d)
Thinking Outside of the Taxonomic Box: Non-Traditional In Vivo Species in Drug Discovery
(2d)
Labiotech.EU
Preclinical Pulse: The research catching our eye in November 2026
(1d)
Zooming out from ovaries: how has renaming PMOS changed lives?
(5d)
How to turn a BIO-Europe meeting into a lasting partnership
(5d)
Bio IT World
Biosecurity Is Too Important to Be Left Unregulated
(13h)
NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation
(1d)
Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award
(4d)
GEN News
How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years
(1d)
From Farm Waste to Medical Nanoparticles
(1d)
Hybrid Model Captures Lactate Run-Away and Back-Metabolism
(1d)
Cure Today
Living With BRCA and Ovarian Cancer: Leanne Citrone's Story
(1h)
Patient Advocacy Advice From a Colon Cancer Survivor
(3h)
Medicare Part D 2027: What a $2,400 Cap Means for Cancer Drugs
(5h)
Contract Pharma
Valo Health Merges with Montai Therapeutics, Company Will Keep Valo Name
(11m)
Neuvivo Appoints Mike McGrath as CEO
(15m)
Devia Spins Out of Visium to Aid Pharma Companies with GxP Deviations
(1h)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1mo)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1mo)
Zerion partner files first EU application for Dispersome‑enabled product
(1mo)
Medcity News
Follow the Leader: How to Build and Retain Great Clinical Teams
(5h)
Oura’s Buys Counsel for $625M, But Will Payers and Consumers Get on Board?
(19h)
FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke
(22h)
Chemical & Engineering News
Sorry, it’s a scam—what to look out for in your job search
(39m)
Periodic Graphics: Fighting flu: How flu vaccines are made
(3h)
C&EN Chempics Close-Ups, Nov. 11
(6h)
The Pharma Letter
VectorY raises 74.5 million euros to take TDP-43 ALS therapy through Phase I/II readout
(2h)
Teva targets $6-7 billion innovative medicines revenue by 2030 at first R&D Day
(3h)
Positive new Phase III data for Amgen’s dazodalibep
(4h)
Targeted Oncology
Dr Garmezy on JNJ-6143's Novel Mechanism in Advanced Prostate Cancer
(35m)
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
(1h)
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
(2h)
MedWatch
Trump’s drug pricing policy could delay new medicines in Europe
(5h)
Two boards are plenty for Lundbeck CEO: “It’s about becoming a better CEO”
(6h)
Lundbeck CEO plays down margin pressure from Vyepti’s success
(6h)
In The Pipeline
Think Before You Degrade
(22h)
Jon Clardy, 1943-2026
(2d)
Antimicrobial Peptides for Fun (?) and Profit (?)
(6d)
Pharmaphorum
Obesity needs a new clinical definition, study finds
(5h)
Google Cloud launches Gemini for Healthcare
(6h)
UK's Levicept builds case for osteoarthritis therapy at ACR
(7h)
Drug Discovery Weekly
UQ technology opens new front in Alzheimer’s and Parkinson’s
(2w)
Why we need to rethink childhood cancer treatments
(2w)
Q3 UK biotech VC heads for record year thanks to megadeals
(2w)
HIT Consultant
WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans
(7h)
TigerConnect Smart Room Suite: Integrating Epic, Cloud Alarm Management, and Bedside AI
(13h)
Oscar Health and HealthEx Leverage TEFCA Individual Access to Bring Medical Records into AI Workflows on Day One
(14h)
Insights: Pink Sheet
Why The EU JCA For AstraZeneca’s Etcamah Took More Than 100 Days
(4h)
Fast Approval, Delayed Start? EU Speeds Modifications To Clear Trial-Blocking Conditions
(4h)
WuXi AppTec Removed From 1260H List, For Now
(13h)
BioXconomy
Optimizing the Affordability Journey: Insights from a Real-World Brand Case Study
(20h)
GoodRx partners with Google Cloud to bring prescription savings into Gemini for healthcare
(3h)
Veristat, Clene use AI to speed up ALS drug application by 80%
(3h)
BioCentury
PepGen’s DM1 readout hints at functional payoff from splicing correction
(19h)
SITC 2026: Dual targeting, precise integration shape in vivo CAR T development
(20h)
FDA approvals on track for record year
(21h)
SCRIP
Oyster Therapeutics Raises $60m To Target Alzheimer’s With Protein Degraders
(2h)
Stock Watch: Lilly’s 52-Week High Meets Alnylam’s 52-Week Low
(2h)
Beam Eyes Risto-Cel BLA As Early As Year-End After Positive Sickle Cell Data
(8h)